New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:38 EDTENDP, BDSIEndo Health trial results more meaningful to partner, says Cantor
Cantor views the positive top-line results from the trial of BEMA buprenorphine reported by Endo Health (ENDP) as more meaningful to its partner, BioDelivery Sciences (BDSI), than to Endo. Cantor see the product opportunity for this drug to be modest and maintains its Sell rating and $43 price target on Endo Health.
News For ENDP;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:01 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:55 EDTENDPEndo initiated with a Buy at Guggenheim
Subscribe for More Information
October 21, 2014
06:37 EDTENDPEndo pullback brings buying opportunity, says Piper Jaffray
Subscribe for More Information
October 14, 2014
11:23 EDTENDPBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
October 13, 2014
10:08 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:41 EDTENDPEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 10, 2014
10:01 EDTBDSIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:01 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:02 EDTBDSIBioDelivery Sciences downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
05:50 EDTENDPEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTENDPAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use